U.S. Degenerative Disc Disease Treatment Market, By Treatment Type, By Disease Indication, By Distribution Channel, By Geography

Description

U.S. Degenerative Disc Disease Treatment Market is estimated to be valued at USD 3.52 Mn in 2026 and is expected to reach USD 5.26 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3.52 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.90%	2033 Value Projection:	USD 5.26 Mn

Degenerative disc disease refers to symptoms of back or neck pain caused by wear-and-tear on a spinal disc. In some cases, degenerative disc disease also cause weakness, numbness, and hot shooting pains in the arms or legs (radicular pain). Degenerative disc disease typically consists of a low-level chronic pain with intermittent episodes of more severe pain. Degenerative disc diseases are very frequent and debilitating disorders, and R&D activities surrounding this disease are highly cost intensive. Hence, many fund raising companies and manufacturers are engaged in raising funds for their research regarding the treatment of degenerative disc diseases. Depending upon the level of pain, degenerative disc disease can be treated with two common processes which are non-surgical and spinal fusion. Non-surgical treatments include medications, physical therapy, and chiropractic care. Whereas, spinal fusion is a procedure used to surgically treat degenerative disc disease.

Market Dynamics

Key players in the market are focused on growth strategies such as product launch and approval which is expected to drive the growth of market over forecast period. For instance, in April 2021, Cerapedics Inc. an ortho-biologics company, announced that the U.S. Food and Drug Administration (FDA) granted breakthrough device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). Moreover, in February 2019, FibroGenesis, a company focused on regrowth of the spinal disc nucleus using its universal donor product CybroCell, announced that the U.S. FDA had cleared its investigational new drug (IND) protocol of CybroCell for human trials in the U.S., considered to be the first IND approval for a fibroblast cell therapy in a chronic condition of degenerative disc disease.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. degenerative disc disease treatment market based on the following parameters - company highlights, financial overview, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. degenerative disc disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. degenerative disc disease treatment market

Market Segmentation

By Treatment Type (Revenue, USD Mn, 2021-2033)
Epidural Steroid Injections
Narcotics
- Morphine
- Methadone Hydrochloride
- Codeine
- Hydrocodone
- Tramodol
- Oxycodone
- Others
Orthobiologics
- Phase I
- Phase II
- Phase III
By Disease Indication (Revenue, USD Mn, 2021-2033)
Early Stage
Mid Stage
Late Stage
By Distribution Channel (Revenue, USD Mn, 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Players
AnGes Inc.
Ankasa Regenerative Therapeutics, Inc.
BIOPHARM GMBH
BioRestorative Therapies Inc.
Biosplice Therapeutics, Inc.
Bone Therapeutics SA
Cerapedics Inc, CO.DON
Creative Medical Technology Holdings, Inc.
DiscGenics Inc.
Eli Lilly and Company
Ferring Pharmaceuticals
FibroGenesis
Geistlich Pharma AG
Harbor View Medical Services, PC
Intralink-Spine, Inc.
Isto Biologics
Johnson & Johnson
Kolon TissueGene Inc.
Kunovus
Lineage Cell Therapeutics, Inc.
Mesoblast
NC Biomatrix BV
Notogen Inc.
Pfizer, Inc.
R3 Stem Cell
Smith & Nephew
Spine BioPharma
Stayble Therapeutics AB
US Stem Cell Inc.
VIVEX Biologics, Inc.

Product Code: CMI4590

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global U.S. Degenerative Disc Disease Treatment Market, By Treatment Type, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Epidural Steroid Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Narcotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  - Morphine
  - Methadone Hydrochloride
  - Codeine
  - Hydrocodone
  - Tramodol
  - Oxycodone
  - Others
Orthobiologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  - Phase I
  - Phase II
  - Phase III

5. Global U.S. Degenerative Disc Disease Treatment Market, By Disease Indication, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Early Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Mid Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Late Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global U.S. Degenerative Disc Disease Treatment Market, By Distribution Channel, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- AnGes Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Ankasa Regenerative Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- BIOPHARM GMBH
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- BioRestorative Therapies Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Biosplice Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bone Therapeutics SA
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Cerapedics Inc, CO.DON
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Creative Medical Technology Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- DiscGenics Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Ferring Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- FibroGenesis
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Geistlich Pharma AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Harbor View Medical Services, PC
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Intralink-Spine, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Isto Biologics
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Kolon TissueGene Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Kunovus
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Lineage Cell Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Mesoblast
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- NC Biomatrix BV
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Notogen Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- R3 Stem Cell
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Smith & Nephew
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Spine BioPharma
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Stayble Therapeutics AB
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- US Stem Cell Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- VIVEX Biologics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views

8. Section

References
Research Methodology
About Us